Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities

AP Kater, C Owen, C Moreno, G Follows… - NEJM …, 2022 - evidence.nejm.org
Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …
被引用次数：151 相关文章

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

AP Kater, C Owen, C Moreno, G Follows… - NEJM …, 2022 - pubmed.ncbi.nlm.nih.gov
Fixed-Duration Ibrutinib-Venetoclax for CLLAmong 211 patients with CLL who received
ibrutinib-venetoclax or chlorambucil-obinutuzumab, there were 22 and 67 progression-free …

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

AP Kater, C Owen, C Moreno, G Follows… - NEJM …, 2022 - publicum.umed.lodz.pl
BACKGROUND GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.

AP Kater, C Owen, C Moreno, G Follows, T Munir… - NEJM …, 2022 - europepmc.org
Fixed-Duration Ibrutinib-Venetoclax for CLLAmong 211 patients with CLL who received
ibrutinib-venetoclax or chlorambucil-obinutuzumab, there were 22 and 67 progression-free …

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

AP Kater, C Owen, C Moreno, G Follows… - NEJM …, 2022 - publicum.umed.lodz.pl
BACKGROUND GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …